4D Molecular: B. Riley's $37 Call Turns FDMT Into a Pure Phase 3 Bet

B. Riley's initiation sharpens FDMT's Phase 3 decision window

A $37 target turns 4D Molecular Therapeutics into less of a concept story and more of a calendar-driven bet.

B. Riley just put a Buy rating on FDMT and set a $37 price target, implying 267.43% upside from the prior close. The broader Street remains constructive, but less aggressive, with a Moderate Buy consensus and an average target of $30.67. From here, the story is less about whether the science is interesting and more about how quickly the Phase 3 readouts arrive.

For wet AMD, that clock is set by two Phase 3 programs. 4FRONT-1 randomization is complete, with topline data expected in H1 2027. The second study still has work to do: 4FRONT-2 enrollment completion expected in H2 2026, and topline data expected in H2 2027. That leaves a positioning window now, before the market gets its first decisive read on whether 4D-150 can materially reduce injection burden.

The debate may intensify before the data do. B. Riley views 4D-150 as substantially de-risked across the two ongoing 4FRONT Phase 3 studies, while skeptics can point to insider selling of 184,811 shares worth about $2.08 million sold over the past 90 days. The balance sheet does much of the reassuring work here: FDMT ended Q1 with $458 million in cash, cash equivalents and marketable securities expected to fund current operating plan into second half of 2028, reducing near-term financing pressure.

What 4D-150 is trying to solve in wet AMD

The product pitch: sustained intraocular delivery after one injection

4D-150 is not a new small-molecule drug. It is a gene therapy designed to have the eye produce its own anti-VEGF protein over time. The candidate uses an intravitreally delivered capsid selected in primates for retinal transduction to carry genes that direct retinal cells to make aflibercept and anti-VEGF-C locally.

That design matters because the target biology is already established in practice. Aflibercept has been dosed more than 64 million times since 2011, so the bet is not on an unproven mechanism. The question is whether sustained delivery can improve on the usual repeat-injection model.

Wet AMD is a burden-driven indication

Wet AMD treatment is defined by repetition. Patients face ongoing injections, and long-term outcomes can weaken despite therapy. In real-world practice, real-world injection frequency falls from 7.2 in year one to a 4.2-4.6 plateau, with approximately 40% of patients off therapy after year one and mean vision turning negative by year three. That is why a durable therapy has commercial appeal: not just because the science is ambitious, but because reducing treatment burden could matter to patients and clinicians.

B. Riley also notes that the Eylea HD and Vabysmo launches on dosing extensions measured in weeks show the market rewards durability. That helps explain why investors are willing to keep watching a gene-therapy approach in this space.

The real Phase 3 hurdle is non-inferiority, not a head-to-head win

The key readout is not asking 4D-150 to outperform aflibercept in a direct vision-improvement race. The trial's 52-week primary endpoint assesses non-inferiority in mean BCVA change from baseline in a comparison against aflibercept 2 mg Q8W. In practical terms, the therapy has to show vision outcomes are at least as good as standard care.

That design also clarifies the main limitation. Because rescue/supplemental aflibercept injections are allowed in both arms, a positive trial could confirm safety and vision preservation without proving a dramatic reduction in injection frequency. That distinction will matter when investors judge whether a statistical success translates into real-world relevance.

4FRONT-2 timing pushes the story closer to a verdict

The schedule is tighter than many investors assumed

A few weeks ago, the timeline still felt open-ended. Now it is more concrete. 4FRONT-2 enrollment completed approximately 4 months ahead of initial projections, the study was over-enrolled, and final patient randomization is expected in Q3 2026.

The first hard signpost is already in view. 4FRONT-1 randomization is complete, with topline data expected in H1 2027. The second study should land in the same decision window, with 4FRONT-2 52-week topline data is expected in H2 2027. The setup is no longer just about promise; it is about proof on a calendar.

Why faster execution cuts both ways

The quicker timetable likely reflects genuine interest. Company officials tied the pace to strong interest from investigators and patients, which supports the idea that unmet need in wet AMD remains high.

But speed also reduces the margin for delay. Final randomization in 4FRONT-2 is still expected later next year, and follow-up will be needed before the 2027 readouts. Investors are not just waiting for data anymore; they are watching whether the schedule holds.

The milestones that matter next

• Final patient randomization is expected in Q3 2026 in 4FRONT-2
• 4FRONT-1 topline data, expected in H1 2027
• 4FRONT-2 52-week topline data is expected in H2 2027

Bulls, bears, and what would actually break the thesis

What bulls are betting on

The bull case rests on a relatively simple idea: if 4D-150 meets its 52-week non-inferiority primary endpoint, the larger upside lies in reducing the injection burden patients already dislike. That is also why B. Riley views the candidate as substantially de-risked across the two ongoing 4FRONT Phase 3 studies.

There is also a trading-structure angle. 99.27% of the company is owned by hedge funds and institutions, so the stock can reprice quickly if the data arrive cleanly and support the story.

What bears are focused on

The bear case is not hard to map. In addition to 184,811 shares worth about $2.08 million sold over the past 90 days, skeptics will focus on whether the trial design allows a positive readout that still leaves the main commercial question unanswered.

Because the study allows rescue/supplemental aflibercept injections in both treatment arms, success may show that 4D-150 can preserve vision without clearly changing long-term injection habits. If that happens, the thesis shifts from clinical success to limited practical impact.

What would confirm or weaken the setup

Confirmation would be a non-inferiority readout plus credible evidence that injection burden fell enough to matter in practice. Weakening of the thesis would be a statistically successful trial that still leaves investors unsure whether clinicians and patients would actually change behavior.

That is the split that matters now. The product rationale was already on the table; B. Riley's initiation simply makes the Phase 3 clock the center of the trade.